Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Price Target at $23.00

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been given an average rating of “Strong Buy” by the five brokerages that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $23.00.

A number of brokerages have recently weighed in on TBPH. Wall Street Zen upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Jones Trading upgraded Theravance Biopharma to a “strong-buy” rating and set a $24.00 price target for the company in a research report on Tuesday, June 17th. B. Riley assumed coverage on Theravance Biopharma in a research report on Friday. They issued a “buy” rating and a $28.00 price target for the company. Zacks Research upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 15th. Finally, BTIG Research lifted their price target on Theravance Biopharma from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, June 27th.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 10,000 shares of Theravance Biopharma stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the completion of the transaction, the senior vice president owned 326,918 shares in the company, valued at approximately $3,723,596.02. This trade represents a 2.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TBPH. Nuveen LLC purchased a new position in shares of Theravance Biopharma during the first quarter valued at approximately $3,348,000. Jefferies Financial Group Inc. boosted its position in shares of Theravance Biopharma by 1,191.9% during the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company’s stock valued at $3,054,000 after buying an additional 255,455 shares during the period. Acadian Asset Management LLC boosted its position in shares of Theravance Biopharma by 121,993.7% during the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company’s stock valued at $1,554,000 after buying an additional 174,451 shares during the period. Qube Research & Technologies Ltd boosted its position in shares of Theravance Biopharma by 80.2% during the second quarter. Qube Research & Technologies Ltd now owns 205,280 shares of the biopharmaceutical company’s stock valued at $2,264,000 after buying an additional 91,341 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in shares of Theravance Biopharma by 30.8% during the second quarter. BNP Paribas Financial Markets now owns 387,472 shares of the biopharmaceutical company’s stock valued at $4,274,000 after buying an additional 91,300 shares during the period. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Up 4.4%

Shares of Theravance Biopharma stock opened at $14.30 on Friday. The firm has a market cap of $720.15 million, a price-to-earnings ratio of 59.58 and a beta of 0.04. The business has a 50-day moving average price of $12.39 and a 200-day moving average price of $10.61. Theravance Biopharma has a twelve month low of $7.88 and a twelve month high of $14.55.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.